Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 3661-3670 Newer>

The Motley Fool May 1, 2007 Brian Lawler	Pay Attention to Noven The drug developer announced results from another quarter of strong growth. Revenue doubled versus the year-ago period as sales of its attention-deficit hyperactivity disorder patch, Daytrana, began to pick up.
The Motley Fool May 1, 2007 Rich Duprey	Dentsply Opens Wide Strong European markets and double-digit specialty product sales boost the dental supply company. Investors, take note.
The Motley Fool May 1, 2007 Rich Smith	The Losses Swell at ViaCell Given that ViaCell has been ramping up its sales and marketing spending for about a year, it's about time ViaCell's stock start showing some results from this "investment."
Chemistry World May 2007 Derek Lowe	In the Pipeline After months of bleak news about faltering pipelines and redundancies, it's time to find reasons to be cheerful about the drug industry.
The Motley Fool April 30, 2007 Brian Lawler	Alexion Heads Overseas Alexion is headed for approval of its lead compound in the European Union. With no other compounds in clinical stage development, an investment in Alexion is all about the market potential for Soliris.
The Motley Fool April 30, 2007 Mike Havrilla	ThermoGenesis Is Ready to Heat Up Shares of ThermoGenesis are currently trading at compelling levels that could produce nice gains if the company receives FDA approvals and subsequently ramps up the sales of its umbilical cord blood stem cell processing machines and ancillary products.
The Motley Fool April 30, 2007 Brian Orelli	No Pain for Endo's Investors Endo Pharmaceuticals had an impressive first quarter thanks to a new product and continued sales growth of its older brands. Investors, take note.
The Motley Fool April 30, 2007 Mike Havrilla	VIVUS Revives Investor Interest New drugs with huge markets could keep shares of VIVUS on their upward trajectory.
Managed Care April 2007	Consumers Upset By High Cost of Administration When it comes to health care administrations, there is a wide gap between what executives of hospitals and insurance companies believe it costs and what consumers believe.
Managed Care April 2007 Martin Sipkof	Abbreviated Approval Process In the Works for 'Biosimilar' Drugs The Access to Life-Saving Medicine Act may be a first step to giving the FDA the legal authority to approve these drugs.
<Older 3661-3670 Newer> Return to current articles.